Time will be of the essence in treating alzheimer disease

JAMA

Volumn 296, Issue 3, 2006, Pages 327-329

  Rosenberg, Roger N ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4;

ADULT; AGED; AGING; ALLELE; ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIFESPAN; NOTE; PRIORITY JOURNAL;

EID: 33746077528     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.3.327     Document Type: Note

References (22)

1. Bacskai BJ, Hickey GA, Skoch J, et al. Four-dimensional imaging of brain entry, amyloid-binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A. 2003;100:12462-12467.
2. Lombardo JA, Stern EA, McLellan ME, et al. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci. 2003;23:10879-10883.
3. Lesné S, Koh MT, Kotilinek L, et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature. 2006;440:352-357.
4. Santacruz K, Lewis J, Spires T, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476-481.
5. Hyman BT, Bacskai BJ, Kajdasz ST, et al. Visualizing amyloid plaques. Neurobiol Aging. 2002;23:S149.
6. Ashe KH. Mechanisms of memory loss in Aβ and tau mouse models. Biochem Soc Trans. 2005;33(Pt 4):591-594.
7. 42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710-713.
8. Holcomb L, Gordon MN, McGowan E, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998;4:97-100.
9. Duff K, Suleman F. Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development. Brief Funct Genomic Proteomic. 2004;3:47-59.
10. Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A. 2005;102:6990-6995.
11. Rosenberg RN. Translational research on the way to effective therapy for Alzheimer disease. Arch Gen Psychiatry. 2005;62:1186-1192.
12. (1-42) protein for Alzheimer disease: genomics predicts the response. JAMA. 2005;294:2352-2353.
13. 42 immunization. Neurology. 2003;61:46-54.
14. Masliah E, Hansen L, Adame A, et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005;64:129-131.
15. Gilman S, Koller M, Black RS, et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553-1562.
16. 42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J Neurol Sci. 2006;244:151-158.
17. 42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55:937-945.
18. 42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001;58:373-379.
19. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC; Cache County Study Investigators. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: the Cache County Study. Arch Gen Psychiatry. 2004;61:518-524.
20. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351-357.
21. Peskind ER, Li G, Shofer J, et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid β-amyloid 42 in adults with normal cognition. Arch Neurol. 2006;63:936-939.
22. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319.